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Microcin C (McC), a natural antibacterial compound consisting of a heptapeptide attached to a modified
adenosine, is actively taken up by the YejABEF transporter, after which it is processed by cellular aminopep-
tidases, releasing the nonhydrolyzable aminoacyl adenylate, an inhibitor of aspartyl-tRNA synthetase. McC
analogues with variable length of the peptide moiety were synthesized and evaluated in order to characterize
the substrate preferences of the YejABEF transporter. It was shown that a minimal peptide chain length of 6
amino acids and the presence of an N-terminal formyl-methionyl-arginyl sequence are required for transport.
In the current ongoing quest for new antibiotics, aminoacyl-
tRNA synthetases (aaRSs) have been regarded as promising
targets (5, 11, 14). The natural antibiotic microcin C (McC)
(Fig. 1, compound 1a) targets an aaRS and has been envisaged
as a lead compound for further development as an antibacte-
rial agent (17). McC consists of a heptapeptide that is cova-
lently linked through a phosphoramidate bond to adenosine,
with, in addition, an aminopropyl moiety esterified to the phos-
phoramidate linker (4). Once inside a sensitive cell, McC is
processed by peptide deformylase and several peptidases that
remove the N-terminal formyl group and the peptide part,
respectively (7). As a result of intracellular processing, the
active compound (compound 2), a modified nonhydrolysable
aspartyl-adenylate, is released. Processed McC is a potent in-
hibitor of aspartyl-tRNA synthetase (AspRS) (8).
McC penetrates the outer membrane of the Escherichia coli
cell mostly through the OmpF porin, but also through other,
yet-unidentified transport systems (M. Novikova, A. Metlits-
kaya, and K. Severinov, unpublished data), and is subsequently
transported through the inner membrane by the YejABEF
transporter (10). YejABEF is the only complex responsible for
McC transport, since yej mutants are highly resistant to McC
and its maturation intermediates and chemical analogues.
While intact McC inhibits the growth of sensitive E. coli cells at
low micromolar concentrations, processed McC does not affect
cell growth, even at millimolar concentrations. Thus, the pep-
tide chain enables McC to function through a Trojan-horse
mechanism by promoting active uptake via the YejABEF
transporter. The recently improved synthetic approach for
the production of McC analogues has led us to investigate the
uptake properties of the Yej transporter in more detail. The
results obtained could be important for further drug develop-
ment, where peptides function as carrier moieties for drugs
that otherwise would not be able to penetrate the bacterial
membranes. Here, we used a number of McC analogues trun-
cated either from their C- or N-terminal sides, or otherwise
modified, to determine the minimal peptide chain length suf-
ficient for facilitated transport by Yej.
MATERIALS AND METHODS
Chemistry. Reagents and solvents were purchased from commercial suppliers
(Acros, Sigma-Aldrich, Bachem, and Novabiochem) and used as provided unless
otherwise indicated. N,N-Dimethylformamide (DMF) and tetrahydrofuran
(THF) were analytical grade and were stored over 4-Å molecular sieves for
drying. For reactions involving 9-fluorenylmethoxy carbonyl (Fmoc)-protected
amino acids and peptides, DMF was used for peptide synthesis (low amine
content). All other solvents used for reactions were analytical grade and were
used as provided. Reactions were carried out in oven-dried glassware under a
nitrogen atmosphere, and the reaction mixtures were stirred at room tempera-
ture unless otherwise indicated.
The 1H and 13C nuclear magnetic resonance (NMR) spectra of the compounds
dissolved in dimethyl sulfoxide-d6 (DMSO-d6) or D2O were recorded on a
Bruker UltraShield Avance 300-MHz or 500-MHz spectrometer. The chemical
shifts are expressed as  values in parts per million, using the residual solvent
peaks (for DMSO, 1H, 2.50 ppm; 13C, 39.60 ppm; for D2O, 1H, 4.79 ppm) as a
reference. Coupling constants are given in hertz. The peak patterns are indicated
by the following abbreviations: bs, broad singlet; d, doublet; m, multiplet; q,
quadruplet; s, singlet; and t, triplet. High-resolution mass spectra were recorded
on a quadrupole time-of-flight mass spectrometer (Q-Tof-2; Micromass, Man-
chester, United Kingdom) equipped with a standard ESI (electrospray ioniza-
tion) interface; samples were infused in 2-propanol–H2O (1:1) at 3 l  min1.
For thin-layer chromatography (TLC), precoated aluminum sheets were used
(Silica gel 60 F254; Merck). The spots were visualized by UV light. Column
chromatography was performed on ICN silica gel, 60 Å, 60 to 200 m. Prepar-
ative high-performance liquid chromatography (HPLC) of peptides was done using
a Waters Xbridge C18 (19- by 150-mm) column connected to a Waters 1525 binary
HPLC pump and a Waters 2487 dual-absorbance detector. The final products were
purified using a PLRP-S 100-Å column connected to a Merck-Hitachi L6200A
intelligent pump. Eluent compositions are expressed as volume/volume. Purity was
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checked by analytical HPLC on an Inertsil ODS-3 (C18; 4.6- by 100-mm) column
connected to a Shimadzu LC-20AT pump using a Shimadzu SPD-20A UV detector.
Recordings were performed at 254 nm and 214 nm. Synthesis of all compounds was
accomplished using the conditions described in the legend to Fig. 2. More detailed
methods can be found in the supplemental material.
Biology: whole-cell activity determinations. Bacteria were grown overnight in
LB medium and cultured again the following day in fresh LB medium or LB
medium containing 5 mM (L)-arabinose. Compounds were titrated in a 96-well
plate using LB medium either with or without 5 mM L-arabinose to dilute the
compounds. To each well, 85 l LB medium with or without 5 mM L-arabinose
was added to a total volume of 90 l. Next, 10 l of bacterial cell culture grown
to an optical density at 600 nm (OD600) of 0.1 was added. The cultures were next
placed into a Tecan Infinite M200 incubator and shaken at 37°C; then, the OD600
was determined after 8 h. All experiments were performed in triplicate.
The bacterial strains used for the evaluations were as follows: E. coli Ara-Yej
(BW39758), expressing the yejABEF transporter upon L-arabinose induction; E.
coli K-12 (BW28357), used as the wild-type control; E. coli yejA, lacking subunit
A of the YejABEF transporter; and E. coli ABN, lacking all three peptidase
genes, pepA, pepB, and pepN.
Aminoacylation experiments. To assess the degree of inhibition of the ami-
noacylation reaction, in vitro tests were performed using the relevant S30 cell
extracts.
Preparation of S30 cell extracts. Cells were grown in 50 ml LB medium. After
centrifugation at 3,000  g for 10 min, the supernatant was discarded and the
pellet was resuspended in 40 ml buffer containing Tris  HCl or HEPES  KOH
(pH  8.0; 20 mM), MgCl2 (10 mM), and KCl (100 mM). The cell suspension
was centrifuged again at 4,800 rpm. This procedure was repeated 2 times. The
pellet was resuspended in 1 ml of a buffer comprised of Tris  HCl or
HEPES  KOH (pH  8.0; 20 mM), MgCl2 (10 mM), KCl (100 mM), and
dithiothreitol (DTT) (1 mM) and kept at 0°C. Then, the cells were sonicated for
10 s and left at 0°C for 10 min. This procedure was repeated 5 to 8 times. The
lysate was centrifuged at 15,000  g for 30 min at 4°C.
FIG. 1. Microcin C (compound 1a), the deformylated variant (com-
pound 1b), and processed McC (compound 2).
FIG. 2. General reaction scheme for the various McC analogues. (i) N--CBZ-L-aminoacyl-(tBu or Boc)-succinimide, DBU in DMF, 6 h, room
temperature (RT). (ii) For R2  Z group, H2, Pd/C in MeOH, 3 h, RT. (iii) For R2  Boc group of TFA/H2O (5:2), 4 h, 0°C to RT. (iv) Et3N.3HF
in THF, 16 h, RT. (v) Protected peptide (1 eq.), HOBt (4 eq.), DIC (4 eq.) and DIEA (2 eq.) in DMF, 16 h, RT. R3 may be either a Boc or formyl
group. (vi) TFA/thioanisole/H2O (90/2.5/7.5), 2 h, RT.
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tRNA aminoacylation reaction. To 1 l of solution containing inhibitor, 3 l
of E. coli S30 extracts was added. Next, 16 l of the following aminoacylation
mixture was added: Tris  HCl (30 mM; pH 8.0), DTT (1 mM), bulk E. coli tRNA
(5 g/liter), ATP (3 mM), KCl (30 mM), MgCl2 (8 mM), and the specified
radiolabeled amino acid (40 M). The reaction products were precipitated in
cold 10% trichloroacetic acid (TCA) on Whatman 3MM papers 5 min after the
aminoacylation mixture was added. The aminoacylation reaction was carried out
at room temperature. Depending on whether processing was needed, variable
time intervals were included between the addition of the cell extract and the
addition of the aminoacylation mixture. After thorough washing with cold 10%
TCA, the papers were washed twice with acetone and dried on a heating plate.
Following the addition of scintillation liquid, the amount of radioactivity was
determined in a scintillation counter.
RESULTS
Design, synthesis, and inhibitory activity of McC analogues
in cell extracts. Acyladenylates are the natural reaction inter-
mediates of aaRSs. Therefore, compounds mimicking acylad-
enylates could inhibit charging of tRNAs with their cognate
amino acids, thus leading to cessation of mRNA translation. A
crucial portion of such an inhibitor scaffold is the linker be-
tween the amino acid and the adenosine moiety, which needs
to be metabolically stable (13). Many different linkers have
been developed as surrogates for the natural labile acylphos-
phate linkage (2, 15, 18). Aminoacyl-sulfamoyl adenosines
were found to be the most potent analogues and proved to be
nanomolar inhibitors of their corresponding aaRSs (3, 12, 16).
When trying to mimic natural McC, we therefore opted for
aminoacyl-sulfamoyl adenosines, as they are more stable and
readily synthesized than aminoacyl-phosphoramidate-adeno-
sine analogues, as found in natural McC (17). Following a
recently developed method for the synthesis of McC analogues
(Fig. 2), a series of compounds were created that were trun-
cated from their C termini (compounds 18 to 23 in Fig. 2; each
compound contains an aspartate as the ultimate C-terminal
residue and lacks the N-formyl group) or from their N termini
(compound 24). To evaluate the role of arginine at the second
position of the peptide, compound 25 was created. The ex-
pected positive effect of the presence of an N-formyl moiety
could be studied via the “full analogue” (compound 26).
In cell extracts prepared from McC-sensitive E. coli, the
addition of these compounds inhibited the tRNAAsp amino-
acylation reaction (Fig. 3). No inhibition was observed in ex-
tracts prepared from cells lacking aminopeptidases A, B, and N
with compounds 1a and 1b or 18 to 26. In contrast, the addition
of compound 7b to mutant cell extracts led to tRNAAsp ami-
noacylation inhibition. This is an expected result, since D-SA
(where D refers to aspartic acid and SA to sulfamoyl adeno-
sine), is a nonhydrolyzable aspartyl-adenylate that can inhibit
AspRS directly, i.e., without processing.
McC analogues targeting AspRS and carrying peptide
chains longer than 7 amino acids were found to be significantly
less stable under acidic deprotection conditions during their
synthetic assembly and thus proved hard to synthesize, which
could be attributed to intramolecular cyclization, resulting in
N3-5	-cycloadenosine (12). Hence, to evaluate McC analogues
carrying a peptide longer than the usual heptapeptide, fMRT
GNAAG-SA (compound 17) was synthesized, with incorpora-
tion of an additional internal alanine and substitution of the
C-terminal aspartate for glycine. This compound could be syn-
thesized using a nonprotected peptide, albeit with a low yield.
In cell extracts, the addition of this compound inhibited the
tRNAGly aminoacylation reaction (Fig. 3, lower panel). Except
for compound 7c, no inhibition was observed in extracts pre-
pared from cells lacking aminopeptidases A, B, and N. Like
D-SA, described above, compound 7c does not require pro-
cessing and therefore can inhibit tRNAGly formation directly.
The results thus indicate that compound 17 targets GlyRS
through formation of glycyl sulfamoyl adenosine generated by
processing in McC-sensitive E. coli cell extracts. The control
heptapeptidic analogue (fMRTGNAG-SA; compound 27)
likewise targets GlyRS.
FIG. 3. (Top two panels) Asp-RS and Gly-RS inhibition in S30
extracts of McC-resistant E. coli cells lacking peptidases A, B, and N.
(Bottom two panels) Asp-RS and Gly-RS inhibition in S30 extracts of
McC-sensitive E. coli cells. In all tests, the different extracts were
incubated with the respective AspRS or GlyRS inhibitors, taking sam-
ples at different time points for evaluation of the aminoacylation re-
action. The amounts of aminoacylated tRNAAsp or tRNAGly were
measured via scintillation counting.
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Antibacterial activity of McC analogues with truncated or
elongated peptide chains. The ability of new compounds to
inhibit the growth of McC-sensitive E. coli was evaluated next.
The assay used to determine the sensitivities to various com-
pounds consisted of measuring the optical densities reached by
identical cell cultures in wells of microtiter plates in the pres-
ence of various concentrations of inhibitors. The assay has
proven to be highly sensitive and reproducible and is superior
to standard tests based on the determination of growth inhi-
bition zones on plates.
Since intracellular transport by YejABEF may limit cell sen-
sitivity to McC and its derivatives, a new E. coli Ara-Yej tester
strain (BW39758) was developed (K. A. Datsenko and B. L.
Wanner, personal communication). In this strain, the genomic
yejABEF operon is under the control of the arabinose-induc-
ible araBAD promoter. We expected that the strain would be
relatively resistant to McC in the absence of inducer but might
be hypersensitive in its presence. To test this expectation, the
sensitivities of Ara-Yej cells and control wild-type E. coli K-12
BW28357 cells to McC (compound 1a) were determined (Fig.
4). Uninduced Ara-Yej cells were practically resistant to up to
1 M McC, the highest concentration used in the experiment.
In contrast, the growth of wild-type cells was visibly inhibited
under these conditions. The addition of 5 mM L-arabinose to
the medium had little effect on the McC sensitivity of wild-type
cells but dramatically increased the sensitivity of the Ara-Yej
strain to a level above that of wild-type cells at matching McC
concentrations (pronounced growth inhibition in the presence
of 0.25 M McC). The results thus indicate that (i) induced E.
coli Ara-Yej is a superior strain for measuring sensitivity to
McC and related compounds (by comparing induced and un-
induced cell growth in the presence of a given concentration of
inhibitor tested) and (ii) the amount of the YejABEF trans-
porter produced by wild-type E. coli during growth in rich
medium indeed limits cell sensitivity to McC and, presumably,
the natural YejABEF substrates are taken up less efficiently, as
well. The latter finding is of potential interest, since it has been
shown that the levels of the yejABEF transcript are subject to
negative regulation by a small RNA, rydC (1), which is involved
in stress response.
In agreement with previous findings, we also observed that
an McC derivative lacking the N-terminal formyl group (com-
pound 1b) was less effective against wild-type cells than the
formylated variant, 1a (Fig. 4). This was likewise demonstrated
with the formylated synthetic McC analogue (compound 26)
versus the nonformylated variant (compound 18). The effect
was also observed (though it was less pronounced) in the case
of the induced Ara-Yej strain.
The antibacterial activities of various McC analogues were
next determined. The activities of new compounds were com-
pared to that of MRTGNAD-SA (compound 18 in Fig. 5), a
previously characterized synthetic McC analogue containing a
sulfamoyl bond instead of the natural phosphoamide and lack-
ing the aminopropyl moiety. Both formylated (compound 26)
and nonformylated (compound 3) MRTGNAD-SA variants
were approximately 10 times less effective than McC. This
difference is likely due to the lack of the aminopropyl group,
which was shown to increase the efficiency of target inhibition
by processed McC (9). Interestingly, uninduced Ara-Yej cells
were partially inhibited by compound 18 at concentrations
above 2.5 M. This could be explained by low expression levels
of the araBAD::yej fusion caused by traces of arabinose in the
LB medium or by the presence of a yet-unknown additional,
low-affinity transporter.
As can be seen, removal of the penultimate McC peptide
amino acid (Ala6) (compound 19) had little effect on antibac-
terial activity. The result thus indicates that the Yej transporter
can recognize McC derivatives with a 6-amino-acid peptide
rather than the 7-amino-acid peptide found in natural McC.
Removal of 2 amino acids (Asn5 and Ala6; compound 20)
strongly decreased antibacterial activity, which, however, re-
mained yejABEF dependent. Removal of additional internal
amino acids of the McC peptide abolished the activity (com-
pounds 21 to 23 [data not shown]).
In contrast to the single amino acid deletion at the C termi-
nus, a variant lacking the N-terminal methionine (compound
24) was biologically inactive, indicating that YejABEF recog-
nizes not just the length, but also the sequence of the peptide
attached to the AMP analogue. Compound 25, lacking Arg2
and containing formylated N-terminal methionine, likewise
was very poorly active.
For each compound, control experiments with McC-resis-
tant cells lacking one of the yej genes or the pepA, -B, and -N
genes were also performed (the sensitivities of these cells were
determined in a standard plate assay) on M63 agar plates. Both
control cells were fully resistant to all compounds, with the
exception of compound 23 (MD-SA), which showed minor
activity against yej cells but no activity against ABN cells,
and compound 7b (D-SA), which is active at concentrations of

100 M against both the wild-type and mutant cells, as ex-
pected (17).
Elongation of the peptide chain by a single amino acid res-
idue, as in compound 17, did not affect its potency. In fact, this
compound was slightly more active than the corresponding
compound 27 containing the heptapeptide (Fig. 4). As ex-
pected, compound 17 proved inactive against E. coli cells with
a disrupted yej gene or cells without functional aminopepti-
dases A, B, and N and is therefore acting through a Trojan-
horse mechanism.
To confirm the mechanism of action, a series of in vitro
FIG. 4. Antibacterial activity of McC (compound 1a) and its non-
formylated variant (compound 1b) assayed with wild-type E. coli in the
presence and absence of added L-arabinose and with induced and
uninduced Ara-Yej cells.
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aminoacylation experiments were performed. As can be ob-
served from Fig. 3, all shortened compounds inhibit tRNA
aminoacylation reactions after a 15-min incubation in cell ex-
tract, sufficient time for processing of natural McC. On the
other hand, no inhibition was observed in cell extracts pre-
pared from ABN cells. This demonstrates again that all of the
shortened compounds, with the exception of D-SA and G-SA,
required the action of PepA, PepB, or PepN for release of the
inhibitor.
The physiological substrate of the YejABEF transporter
(other than McC) is not yet known. Since our data indicate that
McC uptake is peptide length dependent, we attempted to
estimate the optimal length of peptide substrates transported
by YejABEF by setting up in vivo competition between McC
and several MccA-based peptides. To this end, fixed amounts
of McC were deposited on lawns of sensitive cells, along with
increasing concentrations of peptides. The expectation was
that at some point the peptide would outcompete McC, ren-
dering the cells resistant and leading to the disappearance of
growth inhibition zones. In all, five peptides were tried (MRT
GNAN, GMRTGNAN, GGMRTGNAN, G3MRTGNAN,
and G6MRTGNAN). The results indicated that the minimal
peptide concentrations needed for complete protection from
13 M McC (with no inhibition zone observed) were 7 mM
for the peptides MRTGNAN and G6MRTGNAN but three
times lower, or 2 mM, for the other three peptides. The
results are consistent with increased potency of an octapeptide-
based GSA inhibitor and indicate that the preferred peptide
length for YejABEF-mediated uptake is more than 7 but less
than 13 amino acids.
DISCUSSION
As shown previously, the McC peptide part plays an impor-
tant role in endowing the intracellularly active compound 2
with its antibacterial activity. Without the peptide being rec-
ognized by the YejABEF transporter, no activity at micromo-
lar concentrations can be demonstrated, as the phosphoami-
dated nucleoside analogue is not efficiently taken up by the
target cells. This has been demonstrated clearly using cells
carrying mutations in the yej genes coding for the transporter,
which proved resistant to McC, highlighting the necessity of
the transporter for the internalization and antibacterial activity
of compounds 1a and 1b (10). Likewise, this has been demon-
strated for different sulfamoylated nucleoside analogues, like
compound 18, which display strong inhibitory activity in vitro
against cognate aaRSs but proved to be rather weak inhibitors
in cellular antibacterial screens. Site-specific mutagenesis of
the mccA gene coding for the peptide moiety of McC and
providing substitution of the internal amino acid positions gen-
erated multiple active McC variants. Only the C-terminal as-
paragine, which is converted to aspartic acid upon maturation
of McC, proved indispensable (6). The N-terminal formyl me-
thionine was not included in the analysis, since it is essential for
FIG. 5. Antibacterial activities of various shortened McC analogues (compounds 23 to 26) targeting AspRS and of heptamer (compound 27)
and octamer (compound 17) variants targeting GlyRS and assayed with wild-type E. coli in the presence and absence of added L-arabinose and
with induced and uninduced Ara-Yej cells.
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initiation of translation of mccA mRNA. Chemical manipula-
tion of sulfamoylated congeners of McC allows the replace-
ment of the last aspartic acid, enabling inhibition of different
aaRSs (17) and probing of the importance of the N-terminal
methionine residue. Hence, to further delineate the recogni-
tion elements for uptake by the YejABEF transporter, differ-
ent truncated and modified peptides were introduced here to
determine the minimal chain length and best composition for
efficient uptake.
Four important results were obtained in this work. First, it
was shown that the YejABEF transporter is able to transport
larger McC analogues across the bacterial inner membrane,
but there seems to be no recognition of compounds with pep-
tide chains of less than 6 amino acids. We were not able to
investigate to what extent the maximal chain length can be
extended, due to difficulties in synthesizing larger compounds.
However, from a pharmaceutical perspective, this is obviously
of minor importance. Second, if the N-terminal formyl group is
excluded from the McC analogue, a slightly lower activity is
observed. This observation is also consistent with earlier data
that showed that McC (compound 1a) is slightly more active
than nonformylated McC (compound 1b). Third, our data
show that if the N-terminal amino acid of the hexapeptidyl
McC analogue is different from methionine, little or no activity
is observed. In contrast, a hexapeptidyl analogue carrying me-
thionine at the N terminus (compound 19) proved active,
although a 5-fold-higher concentration was required to achieve
the activity levels of parent compound 26. This suggests that
the N-terminal methionine or, more exactly, formyl-methio-
nine (see above) is important to recognition by the YejABEF
transporter. Finally, upon exclusion of arginine from the hexa-
peptide moiety, as in compound 25, the activity is dramatically
decreased compared to compound 26. Therefore, the presence
of an N-terminal formyl-methionine in combination with argi-
nine seems to be important for uptake by the YejABEF trans-
porter. One therefore could speculate that a positive charge is
beneficial at this position. However, the latter result is in con-
trast with the McC variants obtained by mutagenesis, where
Ala2, Ser2, and Trp2 variants also proved active (6). In addi-
tion, and more curiously, compounds 23 and 7b displayed an-
tibacterial activity, albeit at high concentrations, which may be
explained by their small size and hence their ability to diffuse
through the bacterial membrane. The lowest concentrations
for all new products at which inhibition can be detected for the
wild-type E. coli strain can be found in Table 1, highlighting the
different points made above. The results obtained here delin-
eate the recognition properties of the YejABEF transporter,
which proved indispensable for the antibacterial potentials of
different McC analogues. The Trojan-horse mechanism of
McC action, mediated by the transporter, also paves the way
for improving the uptake, and hence the biological activities, of
different toxic entities with otherwise low in vitro and/or in vivo
activity.
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TABLE 1. Lowest concentrations of all analogues at which clear
inhibition could be observed against wild-type
E. coli K-12 (BW28357) cells
Compound (no.) Lowest inhibitoryconcn (M)
McC (1a) 0,25
Deformylated McC (1b) 0,25
fMRTGNAD-SA (26) 0,63
MRTGNAD-SA (18) 0,63
MRTGND-SA (19) 3,13
MRTGD-SA (20) 6,25
MRTD-SA (21) 50
MD-SA (23) 50
D-SA (7b) 100
RTGNAD-SA (24) 50
fMTGNAD-SA (25) 12,5
fMRTGNAG-SA (27) 5
fMRTGNAAG-SA (17) 5
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